ACA Arcosa, Inc.

NYSE arcosa.com


$ 93.80 $ 0.80 (0.86 %)    

Friday, 24-Oct-2025 15:59:54 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 93.86
$ 94.50
$ 87.43 x 5
$ 99.17 x 10
$ 93.70 - $ 95.33
$ 67.99 - $ 113.17
140,451
na
4.6B
$ 1.10
$ 49.93
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-02-2024 06-30-2024 10-Q
6 05-03-2024 03-31-2024 10-Q
7 02-23-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 04-28-2023 03-31-2023 10-Q
11 02-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 04-29-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 04-29-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 08-02-2019 06-30-2019 10-Q
26 05-03-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 arcosa-announces-the-dual-listing-of-its-common-stock-on-nyse-texas

Arcosa, Inc. (NYSE:ACA), a provider of infrastructure-related products and solutions, announced today the dual listing of its c...

 da-davidson-maintains-buy-on-arcosa-raises-price-target-to-120

DA Davidson analyst Brent Thielman maintains Arcosa (NYSE:ACA) with a Buy and raises the price target from $110 to $120.

 arcosa-affirms-fy2025-sales-guidance-of-280b-300b-vs-289b-est

Arcosa (NYSE:ACA) affirms FY2025 sales outlook from $2.80 billion-$3.00 billion to $2.80 billion-$3.00 billion vs $2.89 billion...

 arcosa-q1-adj-eps-049-beats-018-estimate-sales-63200m-beat-61450m-estimate

Arcosa (NYSE:ACA) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.18 by 172.22 p...

 machinery-stocks-are-up-today-whats-going-on

Machinery shares such as Arcosa and Valmont Industries are trading higher Wednesday on news that President Donald Trump would p...

 arcosa-sees-fy2025-sales-2800b-3000b-vs-295b-est

Arcosa (NYSE:ACA) sees FY2025 sales of $2.800 billion-$3.000 billion vs $2.95 billion analyst estimate.

 arcosa-q4-adj-046-misses-076-estimate-sales-66620m-miss-69028m-estimate

Arcosa (NYSE:ACA) reported quarterly earnings of $0.46 per share which missed the analyst consensus estimate of $0.76 by 39.47 ...

 oppenheimer-maintains-outperform-on-arcosa-raises-price-target-to-110

Oppenheimer analyst Ian Zaffino maintains Arcosa (NYSE:ACA) with a Outperform and raises the price target from $105 to $110.

 aca-revises-fy24-revenue-from-260b-272b-to-256b-263b-vs-265b-est

2024 Outlook and GuidanceThe Company made the following adjustments to its full year 2024 guidance to reflect the strategic por...

 arcosa-q3-adj-091-beats-086-estimate-sales-64040m-miss-68252m-estimate

Arcosa (NYSE:ACA) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.86 by 5.81 per...

 barclays-initiates-coverage-on-arcosa-with-overweight-rating-announces-price-target-of-106

Barclays analyst Adam Seiden initiates coverage on Arcosa (NYSE:ACA) with a Overweight rating and announces Price Target of ...

 oppenheimer-maintains-outperform-on-arcosa-raises-price-target-to-105

Oppenheimer analyst Ian Zaffino maintains Arcosa (NYSE:ACA) with a Outperform and raises the price target from $100 to $105.

 stephens--co-upgrades-arcosa-to-overweight-announces-96-price-target

Stephens & Co. analyst Trey Grooms upgrades Arcosa (NYSE:ACA) from Equal-Weight to Overweight and announces $96 price ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION